Printer Friendly

THE LIPOSOME COMPANY, INC. PROMOTES TWO EXECUTIVES; SILVERMAN, WILLIAMS NAMED TO NEW MANAGEMENT POSTS

 PRINCETON, N.J., June 28 /PRNewswire/ -- The Liposome Company, Inc. (NASDAQ: LIPO AND LIPOZ) appointed Edward G. Silverman to the position of senior vice president, strategic operations, and Charles L. Williams to the post of vice president, manufacturing operations announced Charles A. Baker, chairman and chief executive officer.
 In his new position, Mr. Silverman, who had been vice president, strategic planning and business development, is responsible for directing the company's strategic planning, business development and licensing functions. He will also direct the creation of a U.S. marketing and sales operation.
 Mr. Williams, who had been executive director for manufacturing, is now responsible or the manufacture of the company's products in advanced clinical trials, and he also will put into place commercial drug production capabilities to ensure the availability of product at the time the company's therapeutic agents are approved for marketing.
 "Ed's promotion is a reflection of the superb job he has done for The Liposome Company in managing this extremely important function," said Mr. Baker. "A seasoned pharmaceutical industry executive, he contributes to our senior management group with a wealth of experience in a broad range of areas, including strategic planning, product development and marketing, all critical concerns for the future.
 "One of the key components in our corporate strategic plan has been the development of our drug production capability, and in the year since joining the company, Chuck truly has helped us get the job done," added Mr. Baker. "He has overseen the construction of our new Princeton manufacturing facility, which will handle drug production for our clinical trials program, and will direct the preparation of our Indianapolis facility for future large scale commercial manufacturing. He has proven to be a valuable addition to our management team."
 Mr. Silverman, 40, who joined The Liposome Company in 1989, has held a number of marketing and strategic planning positions with such pharmaceutical companies as SmithKline & French Laboratories (now SmithKline Beecham), G.D. Searle & Co., and CIBA-Geigy.
 Prior to joining the company, Mr. Williams, 52, held management posts in manufacturing at Genetics Institute, Hana Corporation, Orthomatrix, Collagen Corporation, and E.R. Squibb & Sons (now Bristol- Myers Squibb).
 The Liposome Company has four drugs currently in clinical trials. ABLC(TM) is in Phase II/III studies for the treatment of systemic fungal infections; Maltec(TM), (formerly TLC G-65) is in Phase II trials in the United States and Phase III trials in Europe for the treatment of Mycobacterium avium-intracellulare (MAI), an infection that eventually strikes 30 to 50 percent of people with AIDS; TLC D-99 has completed phase II for treatment of metastatic breast cancer, and TLC C-53 has completed Phase I trials in preparation for studies in Acute Respiratory Distress Syndrome.
 A leading company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals. The Liposome Company develops proprietary parental pharmaceuticals for the treatment, prevention and diagnosis of life-threatening diseases.
 -0- 6/28/93
 /CONTACT: Edward G. Silverman of The Liposome Company, Inc., 609-452-7060/
 (LIPO)


CO: The Liposome Company, Inc. ST: New Jersey IN: MTC SU: PER

TM-SM -- NY080 -- 6444 06/28/93 17:20 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 28, 1993
Words:516
Previous Article:ROBERT B. WILLUMSTAD NAMED CHAIRMAN AND CEO OF COMMERCIAL CREDIT; MARJORIE MAGNER NAMED PRESIDENT AND CAO
Next Article:SEAGULL ENERGY CORPORATION MAKES ANNOUNCEMENT
Topics:


Related Articles
THE LIPOSOME COMPANY APPOINTS NEW MANUFACTURING EXECUTIVE
LIPOSOME COMPANY NAMES SILVERMAN VP OF STRATEGIC PLANNING
THE LIPOSOME COMPANY APPOINTS DAVID SHAND TO BOARD OF DIRECTORS
ANDREW JANOFF AND JOEL PORTNOFF NAMED VICE PRESIDENTS AT THE LIPOSOME COMPANY
THE LIPOSOME COMPANY NAMES TWO CLINICAL RESEARCH VPs
THE LIPOSOME COMPANY APPOINTS VICE PRESIDENT, INTERNATIONAL OPERATIONS
THE LIPOSOME COMPANY APPOINTS BROOKS BOVEROUX CFO
THE LIPOSOME COMPANY ANNOUNCES RESEARCH MANAGEMENT REALIGNMENT
THE LIPOSOME COMPANY APPOINTS JOSEPH STEWART TO ITS BOARD OF DIRECTORS
THE LIPOSOME COMPANY ANNOUNCES NEW MANAGEMENT APPOINTMENTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters